STENTYS to Report First-Half Results on September 22, 2014 PRINCETON, N.J. and PARIS - August 25, 2014 - STENTYS (FR0010949404 - STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces it will report financial results for the first half of 2014 on September 22, 2014, before the market opening, which is a change from the originally announced date of August 28. The Company already reported its first half 2014 revenues and cash positionon July 24.

Due to the discontinuation of the APPOSITION V trial, as announced on July 31, financial classifications and the auditor review will require additional time to prepare, resulting in a change in the public reporting date.

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart

attack) and complex coronary artery disease. STENTYS' Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low one year mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at www.stentys.com .
This press release contains forward-looking statements about the Company's business. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, including with respect to a pre-market approval for the Company's BMS, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 "Risk Factors" of the Company's
2011 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on August 27, 2013 under number
R.13-040 as such section may be updated from time to time.

STENTYS Stanislas Piot CFO

Tel.: +33 (0)1 44 53 99 42 stan.p@stentys.com

NewCap

Investor Relations / Strategic Communications

Dusan Oresansky / Pierre Laurent

Tel.: +33 (0)1 44 71 94 93 stentys@newcap.fr

STENTYS is listed on Comp. B of the NYSE Euronext Paris

ISIN: FR0010949404 - Ticker: STNT

LifeSci Advisors LLC

Andrew McDonald

Tel: +1.646.597.6987 andrew@lifesciadvisors.com

Page 1 sur 1

distributed by